BCRX · Categories · M&A
BCRX - Mergers and acquisitions
BioCryst Pharmaceuticals Inc. (BCRX) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for BCRX
- Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst PharmaceuticalsProvides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing. The funds from these transactions will enable further advancement of BCX9930, BioCryst's oral Factor D inhibitor, toward filing for registration, expand the development of BCX9930 across multipl
- BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK, RESEARCH TRIANGLE PARK, N.C. and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Royalty Pharma plc (NASDAQ:RPRX) and OMERS Capital Markets (OMERS), today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing. The funds from these transactions will enable further advancement of BCX9930, BioCryst's oral Factor D inhibitor, toward filing for registration, expand the development of BCX993
- Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst PharmaceuticalsNEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO™ (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. Royalty Pharma will provide BioCryst with an upfront cash payment of $125 million and will receive royalties of 8.75% on direct annual net sales of ORLADEYO up to $350 million, 2.75% on sales between $350 million and $550 million, no royalty on
- BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital ManagementNEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO™ (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. Royalty Pharma will provide BioCryst with an upfront cash payment of $125 million and will receive royalties of 8.75% on direct annual net sales of ORLADEYO up to $350 million, 2.75% on sales between $350 million and $550 million, no royalty on